Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?†
Potential conflict of interest: Dr. Chalasani serves currently or served within last 12 months as a paid consultant to Amylin and Mochida in the areas related to NAFLD and NASH. He serves as a paid consultant to several other entities in the area of drug safety. This work is in part supported by K24 DK 069290A to N.C.
No abstract is available for this article.